10-Q: Biotricity Achieves First Operating Profit Amid Growth

Biotricity Inc. reported its first-ever positive profit from operations and fourth consecutive quarter of positive free cash flow, driven by strong revenue growth and improved gross margins.

Summary

• Biotricity Inc. reported revenue of $3,873,993 for the three months ended June 30, 2025, a 21% increase from $3,201,743 in the prior year period.
• Gross profit increased to $3,116,800, up from $2,363,168, with gross margin improving to 80.5% from 73.8%.
• The company achieved a positive profit from operations of $281,945, a significant improvement from a loss of $1,116,846 in the comparable prior year quarter, marking a historical first.
• Net loss attributable to common stockholders substantially decreased to $754,293 from $6,948,292 in the prior year period.
• Net cash used in operating activities significantly decreased to $373,389 from $1,494,240 in the prior year period.
• Free Cash Flow (non-GAAP) was positive at $476,865, marking the fourth consecutive quarter of positive free cash flow.
• The company's accumulated deficit stood at $140,196,078 as of June 30, 2025, with a working capital deficiency of $16,661,781.
• Biotricity was delisted from the Nasdaq Capital Market on August 1, 2024, due to non-compliance with the minimum $35 million market value of listed securities, and its shares are now listed on the OTCQB under the symbol BTCY.
• As of August 13, 2025, the company had 26,567,769 shares of Common Stock and 160,672 Exchangeable Shares outstanding, totaling 26,728,441 voting securities.

Sentiment

Score: 7

Explanation: The company shows significant operational improvements, including its first positive operating profit and consistent positive free cash flow, indicating a strong trajectory towards profitability. However, the persistent 'going concern' warning, accumulated deficit, and Nasdaq delisting remain substantial concerns, tempering overall sentiment.

Positives

• Achieved first-ever positive profit from operations of $281,945 for the three months ended June 30, 2025.
• Reported a 21% year-over-year revenue growth, reaching $3.9 million for the quarter.
• Increased gross margin to 80.5% from 73.8% in the prior year, driven by improved margins on technology fees and device sales.
• Reduced selling, general and administrative expenses by 28% to $2.1 million due to increased spending efficiency.
• Significantly reduced net loss attributable to common stockholders to $754,293 from $6,948,292.
• Generated positive Free Cash Flow of $476,865, marking the fourth consecutive quarter of positive free cash flow.
• Accretion and amortization expenses decreased significantly by $991,156 due to the full amortization of Convertible Notes Series C.
• Recognized a gain of $8,433 upon convertible promissory notes conversion and redemption, a shift from a loss of $127,611 in the prior year.
• Shifted from a net other expense of $230,000 to a net other income of $67,000.
• Continued development and commercialization of Bioflux, Biocore, and Biocare products, expanding sales efforts to 31 U.S. states.
• Awarded a NIH Grant for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure, broadening technology platforms.

Negatives

• Incurred recurring losses from operations, with an accumulated deficit of $140,196,078 as of June 30, 2025.
• Maintained a working capital deficiency of $16,661,781 as of June 30, 2025.
• Received a notice from Nasdaq on August 1, 2024, leading to delisting from the Nasdaq Capital Market due to non-compliance with the minimum $35 million market value of listed securities.
• Increased research and development expenses to $0.7 million from $0.5 million due to new technology development and product enhancements.
• Interest expense increased to $850,254 from $768,673 due to increased borrowings.
• Weighted average number of common shares outstanding increased significantly to 26,284,734 from 14,169,441, indicating potential dilution.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and working capital deficiency.
• The company will need to secure additional funding through public or private equity or debt financings, or collaborations, which may not be available on acceptable terms or at all.
• Future financings may be dilutive to, or otherwise adversely affect, holders of common stock.
• Uncertainty exists regarding the company's future profitability and ability to generate positive cash flow from operating activities.
• The development and commercialization of product offerings are subject to numerous uncertainties, and cash resources could be used sooner than expected.
• The process of developing products is costly, and the timing of progress is uncertain, requiring further regulatory approvals and adequate product sales to support the cost structure.
• One customer comprised 23% of total accounts receivable during the three months ended June 30, 2025, posing a concentration risk.
• The company's bank accounts hold cash balances not covered by United States Deposit Protection Regulation ($306,176 as of June 30, 2025).

Future Outlook

Management anticipates continued revenue growth and improved liquidity through ongoing business development and additional equity and debt capitalization. The company expects to continue devoting significant resources to capital expenditures, research and development, operations, marketing, and sales. Existing cash and anticipated near-term financings are believed to be sufficient for the next twelve months, but additional capital will be sought for business opportunities, operating expenses, intellectual property protection, new business lines, and infrastructure enhancement. There is no assurance that additional funding will be raised on acceptable terms or at all, which could require modification of operating plans or curtailment of development and commercialization.

Management Comments

• "This is the first quarter in the Company's history that it has reported positive profit from operations, before deducting various costs of capital such as interest and dividends."
• "This is the fourth consecutive three-month period in which the Company has reported positive Free Cash Flow."
• "We are optimistic with respect to our revenue growth trajectory and our cost control initiatives, we cannot be certain that we will ever be profitable or generate positive cash flow from operating activities."
• "We believe our existing cash, along with anticipated near-term financings, will be sufficient to continue to meet our needs for the next twelve months from the filing date of this report."

Industry Context

Biotricity operates within the growing remote patient monitoring and telemedicine segments of preventative care, a market highlighted by the COVID-19 pandemic. The company's focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses, particularly cardiac care, aligns with increasing demand for remote healthcare. Its proprietary AI technology for predictive monitoring positions it to capitalize on the projected $208.2 billion healthcare AI market by 2030, addressing the growing stress on healthcare professionals by enabling more efficient patient management and data analysis. The company's insourcing business model aims for efficient market penetration and distribution.

Comparison to Industry Standards

• Biotricity's Bioflux and Biocore devices, with FDA clearance, compete in the mobile cardiac telemetry and Holter monitoring markets. While specific comparable companies are not named, the filing implies a competitive advantage through its 'insourcing business model' and 'state-of-the-art technology' compared to typical remote patient monitoring solutions.
• The company's Bioflux Software II System, engineered to reduce review time from 5 minutes to 30 seconds, aims to improve workflow efficiency and reduce operational costs, potentially setting a benchmark for operational efficiency in cardiac data analysis.
• The NIH Grant for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure positions Biotricity at the forefront of AI integration in cardiac care, a developing area where specific industry benchmarks are still emerging.
• The company's claim of monitoring over two billion heartbeats for atrial fibrillation and benefiting over 28,000 patients diagnosed with afib demonstrates a significant data set and patient impact, which could be a competitive differentiator in the remote cardiac monitoring space.
• The recognition of Bioheart as one of TIME's Best Inventions of 2022 suggests a level of innovation and market recognition comparable to leading consumer health technology products.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings. Litigation, regardless of outcome, can have an adverse impact due to defense and settlement costs, and diversion of management resources.

Related Party Transactions

• Accounts payable and accrued liabilities as of June 30, 2025, and March 31, 2025, included $443,566 and $373,744, respectively, due to a shareholder who is a director and executive of the company.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises, positive impact from improved operational performance and reduced net loss, but negative impact from Nasdaq delisting and ongoing 'going concern' doubt.
• Employees: Continued investment in R&D and sales force expansion suggests job stability and growth opportunities, with stock-based compensation plans in place.
• Customers: Continued product development (Bioflux, Biocore, Biocare) and service enhancements (AI-driven improvements, reduced review time) aim to provide better care and efficiency.
• Creditors: Ongoing 'going concern' doubt and working capital deficiency present a risk, but positive free cash flow and efforts to raise capital may mitigate immediate concerns. Secured loans and collateral agreements are in place.
• Regulatory Authorities: Continued FDA clearances for new technologies are crucial for market access and compliance.

Next Steps

• Continue commercialization of Bioflux, Biocore, and Biocare products.
• Devote significant resources to capital expenditures, research and development, operations, marketing, and sales.
• Expand sales force to address new markets and achieve sales penetration in currently served markets.
• Pursue additional equity and debt capitalization to improve liquidity and fund operations.
• Apply for further FDA clearances for ancillary technologies within the next twelve months, including advanced ECG algorithms and analysis software, and the Biocore 2.0.

Key Dates

Recommendation

Biotricity's latest filing presents a mixed but improving picture. The achievement of its first positive operating profit and four consecutive quarters of positive free cash flow are significant milestones, demonstrating strong revenue growth, improved gross margins, and effective cost control. These operational improvements suggest a positive trajectory for the core business. However, the company continues to face substantial challenges, including a persistent 'going concern' warning, a large accumulated deficit, and the recent delisting from Nasdaq. The ongoing need for additional capital, with potential for further dilution, remains a key risk. For a seasoned investor, the operational progress is encouraging, but the underlying financial fragility and capital market challenges warrant caution. A 'hold' recommendation acknowledges the positive operational momentum while recognizing the significant financial and market risks that still need to be addressed for long-term stability.

Keywords

Remote Patient Monitoring, Medical Technology, Cardiac Monitoring, Telemedicine, AI in Healthcare, Biometric Data, FDA Clearance, Healthcare Diagnostics, Wearable Devices, SaaS, Biocore, Bioflux, Biocare